Enyo Pharma Company

ENYO Pharma is a clinical stage Biotech with a unique drug discovery platform inspired by viruses. The company is conducting three Phase 2 with its lead compound Vonafexor (EYP001, a non-Bile Acid FXR agonist) in Chronic Hepatitis B and in NASH.
Headquarters:
France
Industry:
Genomic and Epigenominc Instabillity